Skip to main content

Advertisement

Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Fig. 2

CSF endo-lysosomal proteins and ubiquitin concentrations in the pilot study. The pilot study included subjects designated as controls (N = 24) or AD (N = 19) based on their CSF AD core biomarker profile. Shown are peptides found to be significantly increased in AD compared to controls; a AP2B1_712–719 (P < 0.001), b AP2B1_835–842 (P < 0.0001), c AP2B1_868–878 (P < 0.001; peptide measured in: AD, N = 7, and control, N = 10), d CTSB_80–87 (P < 0.01), e CTSB_210–220 (P < 0.01), f GM2A_89–96 (P < 0.01), g GM2A_170–179 (P < 0.01), h LAMP2_133–144 (P < 0.01), i LAMP2_281–289 (P < 0.01), j Ubiquitin_12–27 (P < 0.01), and k Ubiquitin_64–72 (P < 0.05). Statistics were calculated using Wilcoxon 2-sample rank sum test and the graphs show Tukey boxplots

Back to article page